Genetic technologies and achieving health for populations

International Journal of Health Services

Volumn 30, Issue 2, 2000, Pages 407-424

  Baird, Patricia A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE TECHNOLOGY; HEALTH CARE; HEALTH CARE POLICY; MEDICAL GENETICS; MEDICAL TECHNOLOGY; PUBLIC HEALTH; REVIEW;

EID: 0034082157     PISSN: 00207314     EISSN: None     Source Type: Journal    
DOI: 10.2190/E3P3-TQ8D-KTDR-NF8K     Document Type: Review

References (68)

1. Evans, R. G., Barer, M. L., and Marmor, T. R. Why Are Some People Healthy and Others Not? Aldine de Gruyter, New York, 1994.
2. Baird, P. A., et al. Genetic disorders in children and young adults: A population study. Am. J. Hum. Genet. 42: 677-693, 1988.
3. United Nations Scientific Committee on the Effects of Atomic Radiation. Report: Genetic and Somatic Effects of Ionizing Radiation. New York, 1986.
4. McKusick, V. A. Online Mendelian Inheritance in Man. OMIM (TM) Center for Medical Genetics, Johns Hopkins University, Baltimore, and National Center for Biotechnology Information, National Library of Medicine, Bethesda, Md., 1996. Available from: http://www3.ncbi.nlm.nih.gov/omim/
5. Rennie, J. Grading the gene tests. Sci. Am., June 1994, pp. 88-97.
6. Erbe, R. W., and Levy, H. L. Neonatal screening. In Emery and Rimoins's Principles and Practice of Medical Genetics, Ed. 3, edited by D. L. Rimoin, J. M. Connor, and R. E. Pyertiz, Vol. 1, Chapt. 29, pp. 581-593. Churchill Livingstone, New York, 1997.
7. Andrews, L. B., et al. Assessing Genetic Risks: Implications for Health and Social Policy. Committee on Assessing Risks, Division of Health Sciences Policy, Institute of Medicine, National Academy Press, Washington, D.C., 1994.
8. McCarrick, P. M. Genetic testing and genetic screening. Scope Note #22. National Reference Center for Bioethics Literature, Kennedy Institute of Ethics, Washington, D.C., 1993.
9. Nuffield Council of Bioethics. Genetic Screening: Ethical Issues. London, 1993.
10. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Report by the American Society of Human Genetics and the American College of Medical Genetics Boards of Directors. Am. J. Hum. Genet. 57: 1233-1241, 1995.
11. Struewing, J. P., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20): 1401-1408, 1997.
12. Hubbard, R., and Lewontin, R. C. Pitfalls of genetic testing. N. Engl. J. Med. 334(18): 1192-1194, 1996.
13. Podell, R. N. Physician's Guide to Compliance in Hypertension. Merck, West Point, Penn., 1975.
14. Cramer, J. A., et al. How often is medication taken as prescribed? JAMA 261: 3273-3277, 1989.
15. Avorn, J., et al. Persistence of use of lipid-lowering medications. JAMA 279(18): 1458-1462, 1998.
16. Becker, M. H. Patient adherence to prescribed therapies. Med. Care 23(5): 539-555, 1985.
17. Pincus, T., et al. Social conditions and self-management are more powerful determinants of health than access to care. Ann. Intern. Med. 129(5): 406-411, 1998.
18. Genetic testing and insurance. Background statement prepared by The American Society of Human Genetic's Ad Hoc Committee on Genetic Testing/Insurance Issues. Am. J. Hum. Genet. 56: 327-331, 1995.
19. Buchanan, A. Choosing who will be disabled: Genetic intervention and the morality of inclusion. Soc. Philosophy Policy 13(2): 18-46, 1996.
20. Marteau, T., and Drake, H. Attributions for disability: The influence of genetic screening. Soc. Sci. Med. 40(8): 1127-1132, 1995.
21. Mahowald, M. B., Levinson, D., and Cassel, C. The new genetics and women. Milbank Q. 74(2): 239-283, 1996.
22. Kitcher, P. The Lives to Come. Simon and Schuster, New York, 1996.
23. Takabayashi, H., et al. Development of non-invasive fetal DNA diagnosis from maternal blood. Prenat. Diagn. 15: 74-77, 1995.
24. Baird, P. A. Individual interests, societal interests, and reproductive technologies. Perspect. Biol. Med. 40(3): 440-451, 1997.
25. Diagnosis of Genetic Disorders by Amniocentesis During the Second Trimester of Pregnancy. Medical Research Council, Report No. 5. Ottawa, n.d.
26. An assessment of the hazards of amniocentesis. Report of the Medical Research Council (London) by their Working Party of Amniocentesis. Br. J. Obstet. Gynecol. 85(Suppl. 2), 1976.
27. NICHD, National Registry for Amniocentesis Study Group. Mid-trimester amniocentesis for prenatal diagnosis: Safety and accuracy. JAMA 236: 1471-1476, 1976.
28. Chodirker, B. N., and Evans, J. A. Maternal serum AFP screening programs: The Manitoba experience. In Current Practice of Prenatal Diagnosis Royal Commission on New Reproductive Technologies, Vol. 13, Chapt. 5. Canada Communications Group, Ottawa, 1993.
29. Cunningham, G. C., and Kizer, K. W. Maternal serum alpha-fetoprotein screening activities of State Health Agencies: A survey. Am. J. Hum. Genet. 47: 899-903, 1990.
30. Holtzman, N. A. Proceed with Caution: Predicting Genetic Risk in the Recombinant DNA Era. Johns Hopkins University Press, Baltimore, 1989.
31. Carson, S. A., and Buster, J. E. Biopsy of gametes and preimplantation genetic diagnosis. Semin. Reprod. Endocrinol. 12(3), 1994.
32. Neumann, P. J., Gharib, S. D., and Weinstein, M. C. The cost of a successful delivery with in vitro fertilization. N. Engl. J. Med. 331(4): 239-243, 1994.
33. Mitchell, A. Clinic to sift out bad genes: Prospective parents to pay $6,500-$9,800 to have embryos screened for risk of disease. Globe and Mail, September 24, 1997, p. 1.
34. Baird, P. A. Altering human genes: Social, ethical, and legal implications. Perspect. Biol. Med. 37(4): 566-575, 1994.
35. McCarthy, M. Gene therapy applied to treatment of HIV-1 infection. Lancet 351: 1709, 1998.
36. Danks, D. M. Germ-line gene therapy: No place in treatment of genetic disease. Editorial. Hum. Gene Ther. 5: 151-152, 1994.
37. Diekema, D. Is taller really better? Growth hormone therapy in short children. Perspect. Biol. Med. 34(1): 109-123, 1990.
38. Lantos, J., Siegler, M., and Cuttler, L. Ethical issues in growth hormone therapy. JAMA 261(7): 1020-1024, 1989.
39. Murray, T. H. Assessing genetic technologies: Two ethical issues. Int. J. Technol. Assess. Health Care 10(4): 573-582, 1994.
40. Wilmut, I., et al. Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810-813, 1997.
41. Blumenthal, D., et al. Relationships between academic institutions and industry in the life sciences - an industry survey. N. Engl. J. Med. 334(6): 368-373, 1996.
42. Cohen, J., et al. Biotechnology: Betting on the genome. Science 275: 767-782, 1997.
43. Shapiro, L. Genetics, genomics, and geneconomics: Market forces and natural selection. Presidential address at the American Society of Human Genetics conference, Baltimore. Am. J. Hum. Genet. 61(4, Suppl.): 32, 1997.
44. Abelson, P. H. Biotechnology in a global economy. Science 255(5043): 381, 1992.
45. Golub, E. S. Ethical considerations arising from economic aspects of human genetics. In Changing Nature's Course: The Ethical Challenge of Biotechnology, edited by G. K. Becker, in association with J. P. Buchanan, Chapt. 6. Hong Kong University Press, Hong Kong, 1996.
46. Hubbard, R., and Wald, E. Exploding the Gene Myth. Beacon Press, Boston, 1993.
47. The Future of Medicine: How Genetic Engineering Will Change Us in the Next Century (special issue). Time, January 11, 1999.
48. Lippman, A. Prenatal genetic testing and geneticization: Mother matters for all. Fetal Diagn. Ther. 8(Suppl. 1): 175-188, 1993.
49. Organization for Economic Co-operation and Development. The Global Human Genome Programme. OECD Forum, Paris, 1995.
50. Cook-Deegan, R. M. The human genome project: The formation of federal policies in the United States, 1986-1990. In Bio-Medical Politics, edited by K. E. Hanna, p. 161. National Academy Press, Washington, D.C., 1991.
51. Krimsky, S. Biotechnics and Society: The Rise of Industrial Genetics. Praeger, New York, 1991.
52. Koretz, G. The unhealthy U.S. income gap. Business Week, November 10, 1997, p. 22.
53. Lynch, J. W., and Kaplan, G. A. Understanding how inequality in the distribution of income affects health. J. Health Psychol. 2(3): 297-314, 1997.
54. Wilkinson, R. G. Unhealthy Societies: The Afflictions of Inequality. Routledge, London, 1996.
55. Kaplan, G. A., et al. Inequality in income and mortality in the United States: Analysis of mortality and potential pathways. BMJ 312(7037): 999-1003, 1996.
56. Kawachi, I., et al. Social capital, income inequality and mortality. Am. J. Public Health 87(9): 1491-1498, 1997.
57. Morone, J. A., and Marmor, T. R. Representing consumer interests: The case of American health planning. In Citizens and Health Care: Participation and Planning for Social Change, edited by B. Checkoway, pp. 39-45. Pergamon Press, New York, 1981.
58. Shapiro, M. F. Regulating pharmaceutical advertising: What will work? Can Med. Assoc. J. 156(3): 359-361, 1997.
59. Galjaard, H. Genetic technology in health care: A global view. Int. J. Technol. Assess. Health Care 10(4): 527-545, 1994.
60. Modell, B. The ethics of prenatal diagnosis and genetic counselling. World Health Forum 11: 179-186, 1990.
61. Angastiniotis, M., Kyriakidou, S., and Hadjiminas, M. How thalassaemia was controlled in Cyprus. World Health Forum 7: 291-297, 1986.
62. Loukopoulos, D. Prenatal Diagnosis of Thalassaemia and the Hemoglobinopathies, p. 83. CRC Press, Boca Raton, Fla., 1988.
63. Kuliev, A. Thalassemia can be prevented. World Health Forum 7: 286-290, 1986.
64. U.S. coalition counters breast gene patents. Nature 381: 265, 1996.
65. Holtzman, N. A., and Watson, M. S. (eds.). Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Johns Hopkins University Press, Baltimore, 1998.
66. Knoppers, B. M., and Chadwick, R. The Human Genome Project: Under an international ethical microscope. Science 265: 2035-2036, 1994.
67. Guidelines on ethical issues in medical genetics and the provision of genetics services. In World Health Organization, Hereditary Diseases Programme, p. 79. WHO, Geneva, 1995.
68. Murray, T. H. The genome and access to health care: Two key issues. In The Human Genome Project and the Future of Health Care, edited by T. H. Murray, M. A. Rothstein, and R. F. Murray, Jr., pp. 209-223. Indiana University Press, Bloomington, 1996.